Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16846250 | 0.85 | PARP1 (0.39) | PARP1MAP4K4HDAC1NR1H2NR1H3 | |
| SCHEMBL16825695 | 0.75 | MAP4K4 (0.46) | PARP1MAP4K4 | |
| SCHEMBL16846148 | 0.71 | PARP1 (0.51) | PARP1NR1H2NR1H3 | |
| SCHEMBL16846173 | 0.67 | PARP1 (0.38) | PARP1NR1H2NR1H3 | |
| SCHEMBL27979284 | 0.65 | NR1H2 (0.46) | MAP4K4HDAC1NR1H2NR1H3GPR119 | |
| SCHEMBL23478575 | 0.64 | DPP4 (0.38) | PARP1MAP4K4HDAC1NR1H2NR1H3 | |
| SCHEMBL18186416 | 0.64 | NR1H2 (0.48) | MAP4K4HDAC1NR1H2NR1H3GPR119 | |
| SCHEMBL16824975 | 0.64 | NR1H2 (0.48) | MAP4K4HDAC1NR1H2NR1H3GPR119 | |
| SCHEMBL18186418 | 0.64 | NR1H2 (0.48) | MAP4K4HDAC1NR1H2NR1H3GPR119 | |
| SCHEMBL16569865 | 0.64 | NR1H2 (0.48) | PARP1MAP4K4HDAC1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | PARP1 3904/4885MAP4K4 3538/4885HDAC1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.